<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292808</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00040577</org_study_id>
    <nct_id>NCT04292808</nct_id>
  </id_info>
  <brief_title>Low Dose Methoxyflurane and Out-Patient Aesthetic Surgery and Facial Filler</brief_title>
  <official_title>An Open-Label Study to Assess the Efficacy and Safety of Low Dose Methoxyflurane (PENTHROX®) for Pain Control During Outpatient Aesthetic Surgeries and Facial Filler Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verso Surgery Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verso Surgery Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to generate real-world evidence on the effectiveness, safety and
      additional parameters of low dose methoxyflurane (PENTHROX®) in: aesthetic surgeries (eg.
      hair transplant, upper blepharoplasty, otoplasty, upper brow lift, and mentoplasty) and
      facial filler injections [eg. hyaluronic acid (HA) and Sculptra®] in an outpatient aesthetic
      practice. This will be an open-label study, with a total of 60 patients undergoing a planned
      outpatient aesthetic surgery or filler injection (30 patients in each group).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing patient satisfaction</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Global assessment of medication performance (gmp)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Penthrox</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low Dose Methoxyflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Methoxyflurane inhaler during out-patient aesthetics surgery or facial dermal fillers.</description>
    <arm_group_label>Penthrox</arm_group_label>
    <other_name>Penthrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Conscious adult patients: ≥ 18 years of age

          2. Patient is scheduled for an outpatient anesthetic surgery (eg. hair transplant, upper
             blepharoplasty, otoplasty, upper brow lift, and mentoplasty) or a facial filler
             injection (eg. HA, and Sculptra®).

          3. Patient should understand the nature of the study and provide written informed consent

          4. Patient is able to follow all study requirements and procedures and complete required
             questionnaires

        Exclusion Criteria:

          1. An altered level of consciousness, due to any cause, including head injury, drugs, or
             alcohol

          2. Clinically significant renal impairment

          3. Women of child bearing potential who are pregnant or peri partum, including labour

          4. A history of liver dysfunction after previous methoxyflurane use or other halogenated
             anesthetics

          5. Hypersensitivity to methoxyflurane or other halogenated anesthetics, or to butylated
             hydroxytoluene

          6. Known or genetically susceptible to malignant hyperthermia or a history of severe
             adverse reactions in either patient or relatives

          7. Clinically evident or potential hemodynamic instability as per the opinion of the
             investigator

          8. Clinically evident respiratory impairment as per the opinion of the investigator

          9. Prior treatment with PENTHROX® within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jack Kolenda, MD</last_name>
    <phone>905-849-7560</phone>
    <phone_ext>2</phone_ext>
    <email>info@versosurgery.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Verso Surgery Centre</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 0A3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Nedine Uweis</last_name>
      <phone>9058497560</phone>
      <phone_ext>2</phone_ext>
      <email>nedine@versosurgery.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Turcott</last_name>
      <phone>9058497560</phone>
      <phone_ext>2</phone_ext>
      <email>info@versosurgery.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Jack Kolenda, MD, FRCS (C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.medsafe.govt.nz/profs/datasheet/p/penthroxinh.pdf</url>
    <description>Penthrox Data Sheet - New Zealand (2017)</description>
  </link>
  <link>
    <url>https://www.medicaldev.com/wp-content/uploads/2015/07/Penthrox-PI-v12.pdf</url>
    <description>Penthrox Product Information - Australia (Version 12)</description>
  </link>
  <link>
    <url>http://purdue.ca/wp-content/uploads/2018/04/PENTHROX-PM-EN.pdf</url>
    <description>Penthrox Product Monograph. 2018</description>
  </link>
  <reference>
    <citation>Romagnoli A, Busque L, Power DJ. The &quot;analgizer&quot; in a general hospital: a preliminary report. Can Anaesth Soc J. 1970 May;17(3):275-8.</citation>
    <PMID>5512851</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

